NDAORALGRANULEPriority Review
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOLOSEC (secnidazole) is an oral nitroimidazole antimicrobial approved in 2017 for treatment of bacterial vaginosis in women. It is a single-dose granule formulation that disrupts bacterial DNA in susceptible organisms. The drug represents a convenient alternative to multi-dose regimens in its therapeutic class.
$0.070MPart D
Peak15.5 years to LOEPeak-stage product with minimal Medicare Part D penetration suggests niche positioning; commercial team likely small and specialized in women's health.
Mechanism of Action
Pharmacologic Class:
Nitroimidazole Antimicrobial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SOLOSEC generates minimal direct job postings (0 linked roles), reflecting its niche market position and small commercial footprint. Career opportunities exist primarily in brand management, field sales, and medical affairs within women's health, but likely at a smaller scale than blockbuster franchises.
Brand ManagerMedical Science Liaison
Worked on SOLOSEC at Evofem Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.